Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics

Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile infection (CDI). Here, we report in a prospective observational cohort study the incidence of CDI and assess potent...

Descripción completa

Detalles Bibliográficos
Autores: van Werkhoven, Cornelis H., Ducher, Annie, Berkell, Matilda, Mysara, Mohamed, Lammens, Christine, Torre Cisneros, Julian, Rodríguez Baño, Jesús, Herghera, Delia, Cornely, Oliver A., Biehl, Lena M., Bernard, Louis, Domínguez Luzón, Ma. Ángeles (María Ángeles), Maraki, Sofia, Barraud, Olivier, Nica, Maria, Jazmati, Nathalie, Sablier, Frederique, Gunzburg, Jean de, Mentré, France, Malhotra-Kumar, Surbhi, Bonten, Marc J. M., Vehreschild, Maria J. G. T., Pujol Rojo, Miquel, ANTICIPATE Study Group
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/177408
Acceso en línea:https://hdl.handle.net/2445/177408
Access Level:acceso abierto
Palabra clave:Malalties bacterianes
Antibiòtics
Microbiota
Bacterial diseases
Antibiotics
id ES_cb2d69a2882d9a4a647eebdb3eb50059
oai_identifier_str oai:diposit.ub.edu:2445/177408
network_acronym_str ES
network_name_str España
repository_id_str
spelling Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibioticsvan Werkhoven, Cornelis H.Ducher, AnnieBerkell, MatildaMysara, MohamedLammens, ChristineTorre Cisneros, JulianRodríguez Baño, JesúsHerghera, DeliaCornely, Oliver A.Biehl, Lena M.Bernard, LouisDomínguez Luzón, Ma. Ángeles (María Ángeles)Maraki, SofiaBarraud, OlivierNica, MariaJazmati, NathalieSablier, FrederiqueGunzburg, Jean deMentré, FranceMalhotra-Kumar, SurbhiBonten, Marc J. M.Vehreschild, Maria J. G. T.Pujol Rojo, MiquelANTICIPATE Study GroupMalalties bacterianesAntibiòticsMicrobiotaBacterial diseasesAntibioticsMicrobiotaTrial enrichment using gut microbiota derived biomarkers by high-risk individuals can improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile infection (CDI). Here, we report in a prospective observational cohort study the incidence of CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007 patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta- lactamase inhibitor, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolones or clindamycin from 34 European hospitals. The estimated 90-day cumulative incidences of a first CDI episode is 1.9% (95% CI 1.1-3.0). Carbapenem treatment (Hazard Ratio (95% CI): 5.3 (1.7-16.6)), toxigenic C. difficile rectal carriage (10.3 (3.2-33.1)), high intestinal abundance of Enterococcus spp. relative to Ruminococcus spp. (5.4 (2.1-18.7)), and low Shannon alpha diversity index as determined by 16 S rRNA gene profiling (9.7 (3.2-29.7)), but not nor- malized urinary 3-indoxyl sulfate levels, predicts an increased CDI risk.Nature Publishing Group2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/177408Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1038/s41467-021-22269-yNature Communications, 2021, vol. 12https://doi.org/10.1038/s41467-021-22269-yinfo:eu-repo/grantAgreement/EC/FP7/115523cc-by (c) van Werkhoven et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1774082026-05-27T06:46:51Z
dc.title.none.fl_str_mv Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
title Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
spellingShingle Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
van Werkhoven, Cornelis H.
Malalties bacterianes
Antibiòtics
Microbiota
Bacterial diseases
Antibiotics
Microbiota
title_short Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
title_full Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
title_fullStr Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
title_full_unstemmed Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
title_sort Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics
dc.creator.none.fl_str_mv van Werkhoven, Cornelis H.
Ducher, Annie
Berkell, Matilda
Mysara, Mohamed
Lammens, Christine
Torre Cisneros, Julian
Rodríguez Baño, Jesús
Herghera, Delia
Cornely, Oliver A.
Biehl, Lena M.
Bernard, Louis
Domínguez Luzón, Ma. Ángeles (María Ángeles)
Maraki, Sofia
Barraud, Olivier
Nica, Maria
Jazmati, Nathalie
Sablier, Frederique
Gunzburg, Jean de
Mentré, France
Malhotra-Kumar, Surbhi
Bonten, Marc J. M.
Vehreschild, Maria J. G. T.
Pujol Rojo, Miquel
ANTICIPATE Study Group
author van Werkhoven, Cornelis H.
author_facet van Werkhoven, Cornelis H.
Ducher, Annie
Berkell, Matilda
Mysara, Mohamed
Lammens, Christine
Torre Cisneros, Julian
Rodríguez Baño, Jesús
Herghera, Delia
Cornely, Oliver A.
Biehl, Lena M.
Bernard, Louis
Domínguez Luzón, Ma. Ángeles (María Ángeles)
Maraki, Sofia
Barraud, Olivier
Nica, Maria
Jazmati, Nathalie
Sablier, Frederique
Gunzburg, Jean de
Mentré, France
Malhotra-Kumar, Surbhi
Bonten, Marc J. M.
Vehreschild, Maria J. G. T.
Pujol Rojo, Miquel
ANTICIPATE Study Group
author_role author
author2 Ducher, Annie
Berkell, Matilda
Mysara, Mohamed
Lammens, Christine
Torre Cisneros, Julian
Rodríguez Baño, Jesús
Herghera, Delia
Cornely, Oliver A.
Biehl, Lena M.
Bernard, Louis
Domínguez Luzón, Ma. Ángeles (María Ángeles)
Maraki, Sofia
Barraud, Olivier
Nica, Maria
Jazmati, Nathalie
Sablier, Frederique
Gunzburg, Jean de
Mentré, France
Malhotra-Kumar, Surbhi
Bonten, Marc J. M.
Vehreschild, Maria J. G. T.
Pujol Rojo, Miquel
ANTICIPATE Study Group
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malalties bacterianes
Antibiòtics
Microbiota
Bacterial diseases
Antibiotics
Microbiota
topic Malalties bacterianes
Antibiòtics
Microbiota
Bacterial diseases
Antibiotics
Microbiota
description Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile infection (CDI). Here, we report in a prospective observational cohort study the incidence of CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007 patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta- lactamase inhibitor, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolones or clindamycin from 34 European hospitals. The estimated 90-day cumulative incidences of a first CDI episode is 1.9% (95% CI 1.1-3.0). Carbapenem treatment (Hazard Ratio (95% CI): 5.3 (1.7-16.6)), toxigenic C. difficile rectal carriage (10.3 (3.2-33.1)), high intestinal abundance of Enterococcus spp. relative to Ruminococcus spp. (5.4 (2.1-18.7)), and low Shannon alpha diversity index as determined by 16 S rRNA gene profiling (9.7 (3.2-29.7)), but not nor- malized urinary 3-indoxyl sulfate levels, predicts an increased CDI risk.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/177408
url https://hdl.handle.net/2445/177408
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1038/s41467-021-22269-y
Nature Communications, 2021, vol. 12
https://doi.org/10.1038/s41467-021-22269-y
info:eu-repo/grantAgreement/EC/FP7/115523
dc.rights.none.fl_str_mv cc-by (c) van Werkhoven et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) van Werkhoven et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419565418545152
score 15,300719

Similares en LA Referencia